# Non-Opioid and Opioid-Sparing Anesthesia: An Educational Evidence Overview > **Educational work by a pre-medical student — not medical advice.** Not a clinical protocol, prescription, or patient handout, and not for patient care. See [DISCLAIMER](DISCLAIMER.md). Collin B. George, pre-medical student | Independent educational portfolio Review draft - 27 October 2026; POFA summary and references revised 5 November 2026 **Educational scope.** This is an independent educational discussion, not clinical guidance, a clinical trial, a validated decision aid, or an institutional publication. No institutional endorsement is claimed. ## Abstract Reducing unnecessary perioperative opioid exposure is a legitimate research question, but avoiding opioids is not itself a clinical outcome. This educational overview distinguishes opioid-free intraoperative anesthesia from opioid-sparing multimodal analgesia and discusses selected evidence on benefits, harms, and generalizability. It reports no original pooled estimates, clinical data, or completed systematic-review process. ## Purpose and method disclosure The purpose is to discuss how perioperative analgesic evidence should be interpreted. Sources are selected examples, not an exhaustive search or a defined review cohort. Search dates, screening decisions, extraction sheets, and independent-reviewer records sufficient to audit the earlier manuscript were not available during this revision. Accordingly, this source does not retain the earlier claims of duplicate independent screening, inter-rater agreement, approximately 1,200 screened records, formal risk-of-bias scoring, or a numerical SANRA self-assessment. No new account of the original review process is asserted. SANRA is an appraisal instrument for narrative reviews; mentioning it does not certify review quality. A narrative review need not be a meta-analysis, and a systematic review need not perform quantitative pooling. ## Definitions and comparison Opioid-free anesthesia usually refers to omission of intraoperative opioids within a defined regimen; definitions vary. Opioid-sparing approaches seek to reduce exposure while preserving adequate analgesia. Neither label determines whether postoperative rescue opioids will be needed. Meaningful comparisons specify procedure, population, intervention components, background regional and systemic analgesia, comparator, rescue treatment, and follow-up. Opioid consumption, pain, nausea, sedation, respiratory events, hemodynamic events, function, and longer-term outcomes are separate domains. A reduction in one domain cannot substitute for assessment of the others. ## Selected evidence and harms The POFA randomized trial compared a dexmedetomidine-based opioid-free regimen with remifentanil-based balanced anesthesia in major or intermediate noncardiac surgery. Its primary composite outcome (postoperative hypoxemia, ileus or cognitive dysfunction within 48 hours of extubation) was more frequent with the opioid-free regimen (122 of 156 patients, 78%, versus 105 of 156, 67%), mostly because of more hypoxemia. The trial was stopped early after five cases of severe bradycardia in the dexmedetomidine group. Postoperative opioid consumption and nausea were lower with the opioid-free regimen, but extubation and postanesthesia care unit discharge were delayed [pofa]. This trial does not establish that all opioid-free regimens are harmful or that opioid avoidance is universally beneficial. It illustrates why regimen-specific benefit-harm assessment is necessary. An international consensus statement treats IV lidocaine for postoperative pain as a high-risk intervention requiring appropriate governance and monitoring. It advises against overlap with other local anesthetic interventions and specifies separation intervals [foo]. A generic multimodal bundle cannot establish the safety of concurrent lidocaine, fascial-plane blocks, or infiltration by a total-dose calculation alone. This overview supplies no dosing schedule. A systematic review and meta-analysis of perioperative gabapentinoids did not support routine use on the basis of clinically meaningful analgesic benefit and identified adverse effects [verret]. That finding should be distinguished from individualized management of an established condition or chronic prescription. ## Interpretation and evidence gaps Results from different operations, doses, definitions, and outcome windows should not be condensed into a universal percentage reduction or a pooled effect without a reproducible extraction and analysis. No such analysis is reported here. Immediate postoperative opioid use cannot establish prevention of persistent postsurgical pain or relapse of opioid use disorder. Evidence for a component does not validate a complete bundle. Applicability to breast implant revision, conventional knee arthroplasty, and robot-assisted arthroplasty must each be examined rather than assumed. Recovery and adverse-event ascertainment need equal attention to opioid exposure. ## Limitations and conclusion This is a limited educational discussion of selected evidence, not a systematic review, practice guideline, or assessment of current standards of care. It is not comprehensive across anesthetic techniques or newer literature. Expanding it into a scholarly narrative review requires source verification, claim-level extraction, a documented search account, and an explicit description of who performed each review activity. The supported conclusion is narrow: opioid exposure is one outcome among several, and claims of improved perioperative care require regimen-specific evidence on pain, recovery, and harms. No universal anesthetic preference or treatment recommendation follows from this overview. ## References [pofa] Beloeil H et al. Balanced opioid-free anesthesia with dexmedetomidine versus balanced anesthesia with remifentanil for major or intermediate noncardiac surgery. Anesthesiology. 2021;134(4):541-551. doi:10.1097/ALN.0000000000003725. https://doi.org/10.1097/ALN.0000000000003725 [foo] Foo I et al. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. Anaesthesia. 2021;76:238-250. doi:10.1111/anae.15270. [verret] Verret M et al. Perioperative use of gabapentinoids for the management of postoperative acute pain: a systematic review and meta-analysis. Anesthesiology. 2020;133(2):265-279. doi:10.1097/ALN.0000000000003428. PMID 32667154. https://doi.org/10.1097/ALN.0000000000003428